Delix Therapeutics Retains KCSA Strategic Communications
KCSA to provide integrated public and investor relations counsel
News provided by
Share this article
Share this article
BOSTON, May 19, 2021 /PRNewswire/ Delix Therapeutics (the Company ), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its agency of record (AOR).
KCSA will implement a comprehensive strategic communications program that aims to educate the investment, biopharmaceutical, and patient advocacy communities on Delix s innovative research and mission. KCSA will assist Delix in advancing the understanding of how non-hallucinogenic analogs of psychedelic compounds can be developed into safe, FDA-approved, take-at-home medicines for the treatment of central nervous system-related conditions.